R. Thomas

发表

Radiofrequency ablation in patients with primary breast carcinoma

F. Izzo, R. Thomas, P. Delrio, 2001, Cancer.

Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients

R. Thomas, D. Miles, F. Nussey, 2003, British Journal of Cancer.

Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.

A Ciarmiello, R. Thomas, G. D'aiuto, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer

R. Thomas, S. Dawson, J. Zalcberg, 2006, Investigational New Drugs.

Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation

R. Thomas, L. Weih, J. Zalcberg, 2003, British Journal of Cancer.

Relationship Between Baseline Rectal Tumor Length and Magnetic Resonance Tumor Regression Grade Response to Chemoradiotherapy: A Subanalysis of the TRIGGER Feasibility Study

R. Thomas, I. Nagtegaal, D. Tait, 2022, Annals of Surgical Oncology.

Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study.

R. Thomas, G. Botti, G. D'aiuto, 2001, Seminars in oncology.

Comparison of weekly cisplatin-epirubicin-paclitaxel (PET) with triweekly epirubicin-paclitaxel (ET) in locally advanced breast cancer (LABC). SICOG 9908 phase III tria.

R. Thomas, A. Russo, A. Petrillo, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly cisplatin-epirubicin-paclitaxel (PET) vs. triweekly epirubicin-paclitaxel (ET) in metastatic breast cancer (MBC). Interim analysis of the SICOG 9908 phase III trial.

R. Thomas, A. Russo, G. Comella, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration for the treatment of large operable breast cancer. SICOG 0105 phase II study.

R. Thomas, M. Rinaldo, M. di Bonito, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).

R. Thomas, P. Vallone, G. Botti, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-Acting versus Short-Acting Cephalosporins for Preoperative Prophylaxis in Breast Surgery:A Randomized Double-Blin d Trial Involving 1,766 Patients

R. Thomas, M. Rinaldo, G. D'aiuto, 1999, Chemotherapy.

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.

R. Thomas, G. Manikhas, C. Rose, 2003, European journal of cancer.

Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.

R. Thomas, G. D'aiuto, G. Botti, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive Biomarkers and Personalized Medicine Ki67Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

P. Fasching, T. Fehm, R. Thomas, 2013 .

A systematic review of generic and breast cancer specific life expectancy models in the elderly.

R. Thomas, A. Pieri, H. Cain, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer

R. Thomas, J. Zalcberg, M. Jefford, 2010, British Journal of Cancer.

Scintimammography with 99mTc-MDP: experience of the National Cancer Institute of Naples.

R. Thomas, G. D'aiuto, S. Lastoria, 1998, European journal of radiology.

A two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration is highly effective in large operable breast cancer. Final analysis of a SICOG phase II study

R. Thomas, G. D'aiuto, M. Bonito, 2005 .

Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study

R. Thomas, G. Botti, G. D'aiuto, 2006, British Journal of Cancer.

Estrogen Receptor-Negative and HER-2/neu-Positive Locally Advanced Breast Carcinoma: Therapy with Paclitaxel and Granulocyte-Colony Stimulating Factor

R. Thomas, G. D'aiuto, G. Comella, 2008 .

Immediate breast reconstruction with the transverse rectus abdominis musculocutaneous flap after skin-sparing mastectomy.

R. Thomas, G. D'aiuto, P. Cortino, 2001, International surgery.

A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study.

R. Thomas, G. Botti, G. D'aiuto, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.